Tan, David S. P.

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 1,197

Biomarkers for Homologous Recombination Deficiency in Cancer

Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 329

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 96

Hereditary breast cancer: From molecular pathology to tailored therapies

Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology

BRCA gene mutations in cancerBreast Lesions and Carcinomas

Cited by 60

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors

Lim, J., & Tan, D. S. P. (2017) · Cancers

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 52